Ascendis Pharma A/S (NASDAQ:ASND) Receives $220.67 Consensus Target Price from Analysts

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has earned a consensus rating of "Buy" from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Fifteen research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have covered the stock in the last year is $220.67.

A number of research firms recently weighed in on ASND. Royal Bank Of Canada boosted their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Wedbush boosted their price target on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and set a $200.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Oppenheimer reaffirmed an "outperform" rating and issued a $224.00 target price (up previously from $215.00) on shares of Ascendis Pharma A/S in a research note on Friday, June 13th. Finally, Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC boosted its holdings in Ascendis Pharma A/S by 3.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock worth $368,000 after purchasing an additional 100 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Ascendis Pharma A/S by 2.3% during the first quarter. PNC Financial Services Group Inc. now owns 8,578 shares of the biotechnology company's stock worth $1,337,000 after purchasing an additional 195 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ascendis Pharma A/S during the fourth quarter worth $28,000. Finally, Brooklyn Investment Group boosted its holdings in Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 273 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $0.97 during trading on Thursday, reaching $174.07. The company had a trading volume of 157,816 shares, compared to its average volume of 501,661. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00. The stock has a market cap of $10.64 billion, a PE ratio of -27.72 and a beta of 0.38. The business's 50 day moving average price is $167.68 and its 200-day moving average price is $152.26.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million. Equities analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.